Intra-Cellular Therapies (ITCI) PT Raised to $70 at Jefferies on Bullish Caplyta Survey
Tweet Send to a Friend
Jefferies analyst Andrew Tsai raised the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $70.00 (from $55.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
